Select a Region North America

Join EVERSANA at BIO-Europe Spring 2022

Join EVERSANA™ virtually at BIO-Europe Spring, March 28-31, 2022. With over 40 clients and a growing number of engagements in Europe, EVERSANA is leading the way as the only end-to-end provider of commercialisation services that span all stages of the product life cycle to deliver long-term value for patients, physicians and payers.

Join our team for virtual networking during BIO-Europe Spring, or watch our experts speak during the following sessions.

  1. Panel Discussion: How Digital Health Technologies Can Support Systemic Change in Healthcare
    Monday, 28 March 2022 13:30 – 14:30 CET 

    Join EVERSANA’s Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine, and fellow panellists as they discuss how digital health technologies impact the patient’s healthcare experience – from how big data applications can help identify at-risk patients to feeding back RWE to inform the drug innovation process. The discussion will also touch on how these technologies can open new ways to provide access to therapeutics in underserved areas such as mental health and chronic diseases.

  2. Panel Discussion: Early-Trial Planning in Times of Pay-for-Performance Agreements & European HTA Harmonization
    Wednesday, 30 March 2022 13:30 – 14:30 CET 

    In this workshop, EVERSANA’s Mike Ryan, Executive Vice President, Europe, and other industry experts will focus on innovative reimbursement for high-cost therapies in Europe. They will outline how mid-sized biotech companies can successfully bring their innovations into the European reimbursement systems through early-study planning. Special emphasis is placed on the harmonization of the health technology assessment (HTA) procedures and the resulting study design requirements. Success factors for pay-for-performance models are also presented.



Stay current with the latest commercialisation news:

Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment

EVERSANA™ expands medical information and integrated compliance services across Europe

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada

Explore services:

U.S. Commercialisation

Assess Commercial Readiness in Europe